Clinical Associate Professor CHFS, CCTN, CCON University of British Columbia
Disclosure(s):
Margot K. Davis, MD, MS, FRCPC, FCCS: Alnylam: Speaker/Honoraria (Ongoing); AstraZeneca: Consultant/Advisory Board (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); BI/Lilly: Consultant/Advisory Board (Ongoing); Eidos: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Ferring: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing)
Session Description: Conundrums in TTR amyloid cardiomyopathy 1. Cardiac TTR amyloid and challenges encountered a. High Clinical suspicion for TTR but “equivocal PYP” b. My very symptomatic 85 yr old has wtTTR i. When is it “to old” to start tafamidis? ii. How to monitor a patient on treatment? iii. FC 3 dyspnea, severe aortic stenosis, LVH and strongly positive PYP-now what? iv. Atrial fibrillation with RVR, FC 3 dyspnea, profound fatigue and intolerance to a BB and Ca blocker-options?
